Key result
Interferon-based therapy for chronic hepatitis C virus infection reduced the risk of heart failure hospitalizations compared to untreated patients.
Why the study?
Does interferon-based antiviral therapy reduce heart failure hospitalizations and cardiovascular events in patients with chronic hepatitis C virus infection?
Cohort (n=83,229)
Does interferon-based antiviral therapy reduce heart failure hospitalizations and cardiovascular events in patients with chronic hepatitis C virus infection?
Answers are grounded in this paper and cite their sources.
BACKGROUND: Although hepatitis C virus (HCV) is a known risk factor for cardiovascular disease, whether antiviral therapy (AVT) can reduce heart failure (HF) hospitalizations is unknown. METHODS AND RESULTS: person-years; P=0.001). CONCLUSIONS: AVT for chronic HCV infection might offer protection against HF hospitalizations, critical vascular events, and cardiovascular death beyond known beneficial effects.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2018) conducted a cohort in Chronic Hepatitis C Virus Infection (n=83,229). Interferon-based therapy vs. Untreated subjects was evaluated on Heart failure hospitalizations (HR 0.58, 95% CI 0.42-0.79, p=0.001). Interferon-based therapy for chronic hepatitis C virus infection reduced the risk of heart failure hospitalizations compared to untreated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: